Medscape Medical NewsAll articles

uMI Panorama

Shanghai United Imaging Healthcare Co.,Ltd. • Radiology • 08/30/2024

510(k)IEC 62304 Class B
FDA Summary PDF

Device Purpose

The uMI Panorama GS is a hybrid PET/CT imaging system designed for comprehensive diagnostic evaluations across oncology, cardiology, and neurology by fusing functional PET data with anatomical CT information. This iteration enhances diagnostic precision and workflow through the integration of multiple advanced AI-driven software algorithms, including improved iterative reconstruction, comprehensive motion correction, extended field-of-view imaging, and CT-less attenuation correction.

Summary

The uMI Panorama is a diagnostic imaging system integrating Positron Emission Tomography (PET) and Computed Tomography (CT) to provide comprehensive functional and anatomical information. PET imaging assesses metabolic and physiological functions by measuring radiopharmaceutical distribution, while CT offers detailed anatomical tomographic data and photon attenuation information critical for PET image correction. The system fuses these modalities for precise anatomical referencing of metabolic findings, assisting healthcare professionals in detecting, diagnosing, staging, planning treatment, and evaluating treatment response for diseases in oncology, cardiology, and neurology, and also supports low-dose CT lung cancer screening. This version of the uMI Panorama GS incorporates significant software enhancements, validated through non-clinical testing and reviews of sample clinical images by board-certified radiologists, which confirmed their ability to produce diagnostically sufficient images as intended. Key updates feature an AI-based Iterative Reconstruction (AIIR) with a 3D Deep Convolutional Neural Network to reduce noise, artifacts, and potentially lower CT radiation dose. Other additions include HYPER Iterative for optimized reconstruction, uExcel DPR for improved PET contrast, Respiratory Motion Correction (RMC) and a comprehensive Motion Management (MM) system to mitigate motion artifacts. An AI-Extended Field of View (AIEFOV) algorithm, proven with extensive data, enhances image quality and SUV accuracy for subjects exceeding the CT scan-FOV. Additionally, CT-less Attenuation Correction (CT-less AC) employs deep learning for PET AC without CT, alongside uKinetics for parametric imaging, Retrospective Respiratory-gated Scan, uExcel Unity for SUV normalization, and uExcel iQC for automated quality control, all expanding the system’s advanced capabilities.

AI Regulatory Concerns

Powered byJev by TypeSafe AI

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

Keywords

PET/CT SystemDiagnostic ImagingAIIR (Deep IR)Motion CorrectionAIEFOVCT-less Attenuation CorrectionIterative ReconstructionDeep LearningQuantitative ImagingOncology

Device Metadata

Submission Number
K241585
Company
Shanghai United Imaging Healthcare Co.,Ltd.
Panel
Radiology
Product Code
N/A
Data Type
Images
Clinical Function
Assessment
AI Function
Generation
AI Subclass
image enhancement

Relevant Clinical Questions

  • Q1. How does the performance of the CT-less Attenuation Correction algorithm compare to traditional CT-based attenuation correction in terms of quantitative accuracy (SUV values) across diverse patient demographics and radiotracers?; What are the specific quantitative improvements in high contrast spatial resolution and low contrast detectability with the updated AIIR (3D-DCNN) in CT, and what is the validated range of CT radiation dose reduction achievable in clinical practice without compromising diagnostic information?; For the AIEFOV algorithm, what is the impact on PET quantification accuracy and image artifact levels when imaging highly truncated anatomy, and are there specific patient body habitus or positioning scenarios where its performance is suboptimal?; How does the integrated Motion Management (MM) system differentiate between and correct for various types of patient motion (e.g., respiratory, bulk, head), and what is its efficacy in improving lesion detectability and volumetric accuracy in dynamic PET studies?; Considering the suite of new AI-driven algorithms (AIIR, uExcel DPR, RMC, AIEFOV, CT-less AC), what is the cumulative effect on total examination time, including image acquisition and reconstruction, and how does this impact overall clinical workflow efficiency?

Risk Classification

ESL Analysis
FDA Device ClassII

FDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Post-§524B but no clear network capability detected

Learn how Parasoft automates IEC 62304 compliance testing →

Cybersecurity Evidence

Powered by SBOMator™

Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.

Cyber Score10/100
SBOM Evidence⚠ Not in summary - likely in full submission per §524B
Cyber Risk Assessment⚠ Not in summary - likely in full submission per §524B
Postmarket Plan⚠ Not in summary - likely in full submission per §524B
§524B ApplicableYes

Supply Chain BOM Evidence

Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.

SBOMSoftware Bill of Materials
- Not detected
ML-BOMMachine Learning Bill of Materials(deep learning, neural network, algorithm)
✓ Detected
SaaSBOMSoftware-as-a-Service Bill of Materials(network)
✓ Detected
HBOMHardware Bill of Materials
- Not detected
CBOMCryptography Bill of Materials
- Not detected
VDR/VEXVulnerability Disclosure Report / Vulnerability Exploitability eXchange
- Not detected
OBOMOperations Bill of Materials
- Not detected

Analysis:

• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.

• Evidence of ML-BOM, SaaSBOM detected in AI-generated device summary.

• SBOM not mentioned in AI-generated device summary. Under §524B (effective Oct 2023), cyber devices must provide a SBOM.

• Cybersecurity risk assessment not referenced in AI-generated device summary. FDA cybersecurity guidance (2023) expects this for cyber devices.

• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.

• Not detected in AI-generated device summary: SBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.

Preparing a similar submission?

ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.

Assess Your Readiness →Or contact ESL directly
uMI Panorama - Shanghai United Imaging Healthcare Co.,Ltd. | ESL FDA AI Device Intelligence